• Treatment of inflammatory diseases of the pelvic organs, due to mixed infection

Treatment of inflammatory diseases of the pelvic organs, due to mixed infection

HEALTH OF WOMAN. 2016.6(112):134–143; doi 10.15574/HW.2016.112.134

Treatment of inflammatory diseases of the pelvic organs, due to mixed infection

Romashchenko O. V., Vozianova S. V., Rudenko A. V., Yakovenko L. F. 
SI «Institute of urology of National Academy of medical Sciences of Ukraine», Kyiv

Today the marked increase in the frequency of inflammatory diseases of the pelvic organs (IDPO) caused by sexually transmitted infections (STIs). And among the factors is dominated by numerous microbial associations (mixed infection) in 65-70% of cases detect Chlamydia, gonorrhea, Trichomonas, Molykote. The advantage of latent flow IDPO caused by these factors is one of the reasons for untimely and inadequate treatment of the inflammatory process of the genital organs and the formation of a range of violations of reproductive health of women.

The aim of the study: the rationale for differentiated approaches to the treatment of chronic IDPO caused by mixed infection.

Materials and methods. A survey of 72 women aged 18 to 37 years with IDPO with disease duration from 2 to 11 years. According to etiological factors and clinical course of HSTMT allocated groups were examined: First, the core group of 38 women with HSTMT caused by mixed infection in combination with Chlamydia, Molicutas; the SECOND main group – 34 patients with HSTMT caused by mixed infection in combination with Trichomonas.

Results. Studies have shown that chronic inflammatory diseases of the genital organs in women are predominantly polietiologichesky nature; the latter determines the characteristics of the disease and its consequences. According to clinical and preclinical guidelines inflammatory diseases of the genital organs, caused by mixed infection, defined by differentiated approaches to the choice-stage anti-inflammatory therapy.

Conclusion. Among the factors contributing to the effectiveness of treatment of inflammatory diseases of the genital organs, caused by mixed infection, should be highlighted: 
1. Early diagnosis of the disease.
 
2. Identification and remediation of all sources of infection.
 
3. Compliance with phasing of conducting anti-inflammatory therapy.
 
4. The restoration of microbiocenosis of intestines, vagina, urethra with the use of the drug Laktovit Forte.
 
5. The correction of immunological disorders, the recovery of local immune defense.
 
6. Examination and the simultaneous treatment (if necessary) partner (partners).
 
7. Clinical, microbiological control of effectiveness of the treatment for 3 months; immunological control after 3, 6 months after treatment.
 
Introduction to practical healthcare system of reasonable effective treatments for VSAT based on objective results of clinical and laboratory diagnostics, account etiological factors, state of systemic and local immunity, pathogenesis mechanisms of development of inflammatory process will contribute to the prevention of its chronicity and relapse.

Key words: inflammatory diseases of the pelvic organs, mixed infection, treatment, Tiflox, Meratin.

REFERENCES

1. Saghi-Nejad H, Wasstrman M, Weidner W, Richardsson D, Goldmeier D. 2010. Sexually Transmitted Diseases and sexual function. Journal of Sexual Medicine 7:389–413. http://dx.doi.org/10.1111/j.1743-6109.2009.01622.x; PMid:20092446

2. Ledger W, Witkin S. 2010. Vulvovaginal infection. Manson Pablishin Ltd:127.

3.Verit FF, Verit A, Yeni E. 2006. The prevalence of sexual dysfunction and associated risk factors in women pelvic pain: A cross– sectional study. Archives of Gynecology and Obstetriqs 274:297–302. http://dx.doi.org/10.1007/s00404-006-0178-3; PMid:16705463

4. Henry-Suchet J. 1999. MST: Depistage et Traitement precices. Contracept. Fertil.Sex. 20;1:61–66.

5. Markos AR. 2005. The concordance of Chlamydia trachomatis genital infection between sexual partners, in the era of nucleic acid testing. Sex Health 2:23–24. http://dx.doi.org/10.1071/SH04030; PMid:16334709

6. Global prevalence incidence of selected curable sexually transmiitted infections. WHO report, Geneva 2012.

7. Pennehouat G, Joly-Guillou ML, Mohseni H, Taarji HB, Madelenat P. 2002. Treatment of genital infections in gynecology. Gynecol Obstet Fertil. 30;9:744–749.

8. Delcroix M. 1997. Infections gynecologyques. Paris:342.

9. Henry-Suchet J. 1994. L`infection en gynecologie. Paris:176.

10. Romashchenko OV, Rudenko AV, Biloholovska VV, Khimich VI, Antoshyna TM. 2003. Diahnostyka zapalnykh zakhvoriuvan sechovyvidnykh shliakhiv ta henitalii u zhinok. Zbirnyk naukovykh prats Asotsiatsii akusheriv-hinekolohiv Ukrainy. K, Intermed:271–273.

11. Rudenko AV, Romashchenko OV, Romanenko AM, Biloholovska VV, Kuzmenko AIe. 2003. Rol infektsiinykh faktoriv u formuvanni porushen reproduktyvnoho zdorov`ia sim`i. PAH:2.

12. Workowski KA, Berman SM. 2006. Sexually transmitted dieases traetment guidelines. MMWR Recomm. Rep. 55:1–94. PMid:16888612

13. Romashchenko OV. 2000. Zapalni zakhvoriuvannia henitalii u divchat ta pidlitkiv (etiolohiia, patohenez, prohnozuvannia, likuvannia). Avtoref. dys. d-ra med. nauk. K:36.

14. Wasserheit JN. 1987. Pelvic inflammatory diseases and infertility. Am Med J. 36;7:58–63.

15. Romashchenko OV, Rudenko AV, Ivaniuta LI, Romanenko AM, Nosov AT. 1990. Kliniko-morfolohichne spivstavlennia rezultativ obstezhennia tkanyn matkovykh trub u khvorykh z bezpliddiam v zalezhnosti vid vydu zbudnyka. Pediatriia, akusherstvo ta hinekolohiia 2:62.

16. Romaschenko OV. 2012. Pereotsenka podhodov k diagnostike i lecheniyu vospalitelnyih zabolevaniy genitaliy, obuslovlennyih hlamidinoy infektsiey, s uchetom Evropeyskih rekomendatsiy. Reproduktivnaya endokrinologiya 1(3):51–58.

17. Rudenko AV, Romashchenko OV, Romanenko AM, Yakovenko LF, Spivak MIa. 2002. Suchasni pidkhody do diahnostyky zapalnykh zakhvoriuvan orhaniv maloho taza u zhinok. Seksolohyia y androlohyia. K:272–277.

18. Epling J. 2001. What is the best way to treat trichomoniasis in women? Am Fam Physician. 7:1241–1244.

19. Schwebke JR. 2002. Update of trichomoniasis. Sex Transm Infect. 5:378–379. http://dx.doi.org/10.1136/sti.78.5.378; PMCid:PMC1744553

20. European Guidelines for the Management of pelvic Inflammatory Disease, 2010 update.

21. Ross J, Judline P, Nilas L. 2007. Eropian guideline for the management of pelvic inflammatory disease. Int J STD AIDS. 18:662–666. http://dx.doi.org/10.1258/095646207782193911; PMid:17945043

22. Center for Disease control and Prevention. Sexually Transmitted Diseases Treatment Guidlaines.MMWR Weekly issue. 2010:17–59.

23. Forna F, Gulmezoglu AM. 2003. Interventions for treating trichomoniasis in women. Cochrane Database Syst Rev. 2:CD000218. http://dx.doi.org/10.1002/14651858.cd000218

24. Kogan BG, Bondarenko YuG. 2007. Nitromidazolyi vchera i segodnya – 50 let v borbe s trihomoniazom. Reproduktivnoe zdorove zhenschinyi 5(34):2–9.

25. Moodley P, Wilkinson D, Connolly C, Moodley J, Sturm AW. 2002. Trichomonas vaginalis is associated with pelvic inflammatory disease in women infected with human immunodeficiency virus. Clin Infect Dis. 4:519–522. http://dx.doi.org/10.1086/338399; PMid:11797180

26. Meri T, Jokiranta T, Suhonen L. 2000. Resistance of Trichomonas vaginalis first three cases from Finland and optimization of vitro suscetibility testing under oxygen concentrations. J.Clin.Microbiol. 38;2:763–767. PMid:10655382 PMCid:PMC86198

27. Belkova YuA, Kozlov SN. 2007. Obschie podhodyi k terapii infektsii, vyizvannoy rezistentnyimi k metranidazolu shtammami Trichomona vaginalis. Farmateka 14(144):20–24.

28. Schmid G, Narcisi E, Mosure D, Secor WE, Higgins J, Moreno H. 2001. Prevalence of metronidazole-resistant Trichomonas vaginalis in a gynecology clinic. J Reprod Med. 6:545–549. http://dx.doi.org/10.1097/00006254-200111000-00015

29. Boychuk AV. 2006. Mikst-infektsiya v akusherstve i ginekologii i sovremennyie podhodyi k lecheniyu. Zdorov‘ya zhInki 27:43–47.